Biotech | March 11, 2022
Moderna begins Phase 2 study of Omicron-specific bivalent booster
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
As the Covid-19 pandemic continues to have a disproportionate impact on women, Organon issues a call to action for other leaders to create opportunities to focus on women’s health
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
Collaboration in the industry needs to be institutionalised to drive the growth.
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
It is being developed by Pune-based Gennova Biopharmaceuticals
Subscribe To Our Newsletter & Stay Updated
